The file's text, extracted by GovTribe without its formatting.
BPA
| UF BPA NDC Price List for the May 2024 DoD P&T Meeting | | | |
| DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | P&T Committee Meeting: | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | Quotes due: | April 12, 2024 |
| Formulary Notes | | | |
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. | | | |
Step Therapy Addendum: Agents designated Non-Formulary and/or agents with RFQ not submitted or selected may be designated non step-preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
| Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #3 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
| Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #5 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
| Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #9 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
| Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #10 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1UF1M | Uniform Formulary | 1 or more | | | NO QUOTE |
| 243GIGIG1NF1M | Non-Formulary | 1 or more | | | NO QUOTE |
| | | | If cell highlights red, please confirm intent not to submit a quote | | |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2024 DoD P&T Meeting | | | |
| DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | P&T Committee Meeting: | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | Quotes due: | April 12, 2024 |
| Formulary Notes | | | |
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. | | | |
Step Therapy Addendum: Agents designated Non-Formulary and/or agents with RFQ not submitted or selected may be designated non step-preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | | GASTROINTESTINAL STEROIDS | | Quotes due: | | April 12, 2024 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| Scenario 1: One agent may be placed before the step. | | | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
ADP (WAC Discount)
| UF ADP Appendix for the May 2024 DoD P&T Meeting | | | |
| DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | P&T Committee Meeting: | May 1-2, 2024 |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | Quotes due: | April 12, 2024 |
| Formulary Notes | | | |
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. | | | |
Step Therapy Addendum: Agents designated Non-Formulary and/or agents with RFQ not submitted or selected may be designated non step-preferred.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | GASTROINTESTINAL-1 AGENTS | | P&T Committee Meeting: | May 1-2, 2024 | |
| DOD Uniform Formulary Subclass: | GASTROINTESTINAL STEROIDS | | Quotes due: | April 12, 2024 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| Scenario 1: One agent may be placed before the step. | | | | | | |
| Scenario 1 | 243GIGIG1T21M | Tier 2 | 1 or more | | | |
| 243GIGIG1T31M | Tier 3 | 1 or more | | | |
| | | | | If cell highlights red, please confirm intent not to submit a quote | |